# K151158: ALP VasQcare Take Home System

- Pathway: 510(k) (Traditional)
- Applicant: Currie Medical Specialties, Inc.
- Decided: Dec 10, 2015 after 223 days
- Product code: JOW (Sleeve, Limb, Compressible)
- Device class: 2
- Regulation: 21 CFR 870.5800
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 5 generations back to K915638 (1992). 17 ancestors in all.
No later device cites it as a predicate yet.
0 of 18 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K112311: Alp 501 RB Pump System, Currie Medical Specialties, Inc. (2011) Summary page 4.
- K133274: Vena Pro, Innovamed Health, LLC (2014) Summary page 4.
- K061125: Dvtcare CA5, Doctors Orders (2006) Summary page 4.

## Indications for use
The Alternating Leg Pressure® (ALP®) VasQcare™ System is a non-invasive system for reducing the incidence of deep vein thrombosis. The application of external intermittent pneumatic compression has six effects: 1. Increases blood flow velocity 2. Reduces the risk of deep vein thrombosis 3. Enhances blood circulation 4. Reduces pain and swelling 5. Reduces wound healing time 6. Aids in the treatment and healing of stasis dermatitis, venous stasis, arterial and diabetic leg ulcers, chronic vein insufficiency and reduction of edema in the lower limbs The ALP® VasQcare™ System consists of a pump and a pair of single use calf sleeves. The pump provides intermittent cycles of compressed air, which alternately inflate the calf sleeves. The compression, when applied properly to the patient, increases blood velocity back to the heart and helps to prevent deep vein thrombosis. The pump operates on timed cycles consisting of approximately 12 seconds of inflation where the calf sleeve compresses the limb followed by approximately 48 seconds of deflation where there is no pressure applied to the limb. Each limb compresses once per minute. The ALP® VasQcare™ System may be used on patients at risk for developing deep vein thrombosis and in conjunction with medical therapy for high-risk patients.

Source page: https://510kreport.com/device/K151158
Methodology: https://510kreport.com/methodology